首页|期刊导航|海南医科大学学报|靶向抑制KDM1A调控肿瘤恶病质骨骼肌降解的作用机制研究

靶向抑制KDM1A调控肿瘤恶病质骨骼肌降解的作用机制研究OA

Mechanism of targeted KDM1A in regulating skeletal muscle degradation during cancer Cachexia

中文摘要英文摘要

目的:探讨组蛋白赖氨酸特异性去甲基化酶1A(KDM1A)在肿瘤恶病质骨骼肌降解中的调控作用及其分子机制.方法:构建肿瘤恶病质小鼠模型与C2C12肌管细胞模型,随机分为4组:正常组(NC)、正常给药组(NC+KDM1Ai)、恶病质组(CC)、恶病质给药组(CC+KDM1Ai),通过RNA测序与生物信息学分析确定 KDM1A对骨骼肌的关键调控功能;qPCR、Western blot、免疫荧光实验检测 KDM1A、MuRF-1、Atrogin1表达水平;免疫荧光、苏木素-伊红(H&E)染色实验评估小鼠骨骼肌纤维横截面积(CSA)和肌管细胞直径;Western blot实验检测STAT3、pYSTAT3、H3K4me1、H3K4me2、H3K9me1、H3K9me2表达水平深入探究 KDM1A.结果:转录组数据分析显示 KDM1A在肿瘤恶病质骨骼肌萎缩进程中发挥特异性功能.在小鼠与细胞肿瘤恶病质模型中,KDM1A、MuRF-1、Atrogin1的 mRNA 与蛋白表达水平明显上调(P<0.05).抑制KDM1A可明显改善肿瘤恶病质小鼠体重下降速度及瘦体重、后肢肌肉重量、股四头肌重量、心脏重量和抓握力等指标(P<0.05).在体内和体外实验中,抑制KDM1A后,小鼠肌纤维横截面积明显增大,肌管细胞直径明显增加,MuRF-1和Atrogin1的mRNA与蛋白表达水平明显下调(P<0.05).与恶病质组相比,恶病质给药组组蛋白H3K4me1、H3K9me1和H3K9me2修饰水平明显上调(P<0.05),组蛋白甲基修饰水平改善.抑制 KDM1A后,磷酸化 STAT3表达水平明显下调(P<0.05),STAT3信号通路被抑制.结论:KDM1A在肿瘤恶病质进程中表达上调并促进肌萎缩,抑制KDM1A对肿瘤恶病质骨骼肌降解起保护作用,组蛋白甲基化修饰水平的改善和STAT3信号通路的抑制是其发挥作用的可能机制.

Objective:To explore the regulatory role and molecular mechanism of Histone lysine-specific demethylase 1A(KDM1A)in skeletal muscle wasting during cancer cachexia.Methods:Cancer cachexia mouse models and C2C12 myotube mod-els were established and randomly divided into 4 groups:NC,NC+KDM1Ai,CC,CC+KDM1Ai.RNA sequencing and bioinfor-matics analysis were performed to identify the key regulatory functions of KDM1A in skeletal muscle.qPCR,Western blot and im-munofluorescence were used to detect the expression levels of KDM1A,MuRF-1,and Atrogin1.Immunofluorescence and H&E staining were employed to evaluate the cross-sectional area(CSA)of skeletal muscle fibers and myotube diameter in mice.West-ern blot was conducted to analyze the expression of STAT3,phosphorylated STAT3(pYSTAT3),and histone methylation marks(H3K4me1,H3K4me2,H3K9me1,H3K9me2)to elucidate the regulatory mechanism of KDM1A.Results:Transcrip-tomic data analysis revealed that KDM1A plays a specific role in muscle wasting during cancer cachexia.Both in vivo and in vitro cancer cachexia models,the mRNA and protein expression levels of KDM1A,MuRF-1,and Atrogin1 were significantly upregu-lated(P<0.05).Inhibition of KDM1A markedly improved cachexia-related parameters in tumor-bearing mice,including the rate of body weight loss,lean mass,hindlimb muscle weight,quadriceps weight,heart weight,and grip strength(P<0.05).In both animal and cellular experiments,KDM1A inhibition significantly increased the CSA of muscle fibers and myotube diameter,while downregulating the mRNA and protein levels of MuRF-1 and Atrogin1(P<0.05).Compared to the cachexia group,the inhibitor-treated cachexia group exhibited upregulated histone methylation levels(H3K4me1,H3K9me1,and H3K9me2),indicating im-proved histone methylation.KDM1A inhibition significantly reduced phosphorylated STAT3 levels(P<0.05),suggesting sup-pression of the STAT3 signaling pathway.Conclusion:KDM1A is upregulated during cancer cachexia and promotes muscle atro-phy.Inhibition of KDM1A exerts a protective effect against muscle wasting in cancer cachexia,potentially through restoring his-tone methylation and inhibiting the STAT3 signaling pathway.

董伟;王菲;何美薇;黄志强;王宏伟

南京大学医学院,江苏 南京 210003南京大学医学院,江苏 南京 210003南京大学医学院,江苏 南京 210003南京大学医学院,江苏 南京 210003南京大学医学院,江苏 南京 210003

医药卫生

肿瘤恶病质骨骼肌萎缩KDM1A组蛋白甲基化修饰STAT3信号通路

Cancer cachexiaSkeletal muscle atrophyKDM1AHistone methylationSTAT3 signaling pathway

《海南医科大学学报》 2026 (13)

969-978,10

This study was supported by the General Program of the National Natural Science Foundation of China(82070912) 国家自然科学基金面上项目(82070912)

10.13210/j.cnki.jhmu.20250515.001

评论